• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于HIV-1 DNA的疫苗可诱导CD8介导的跨亚型细胞毒性T淋巴细胞反应。

HIV-1 DNA based vaccine induces a CD8 mediated cross-clade CTL response.

作者信息

Boyer J D, Chattergoon M, Shah A, Ginsberg R, MacGregor R R, Weiner D B

机构信息

Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.

出版信息

Dev Biol Stand. 1998;95:147-53.

PMID:9855425
Abstract

Novel approaches for the generation of more effective vaccines for HIV-1 are of significant importance. In this report we analyse the immunogenicity and efficacy of a DNA vaccination approach in a chimpanzee model system. Three chimpanzees were vaccinated with DNA constructs which express the env, rev, gag and pol proteins. These animals developed specific cellular responses to these proteins, although the nature of the responses varied among the animals. We demonstrated that DNA vaccination led to a CD8 mediated killing of targets expressing the homologous clade B envelope as well as targets expressing heterologous clade E envelope. In addition seronegative individuals have been inoculated with a DNA construct which expresses the env, rev proteins. These studies serve as an important benchmark for the use of DNA vaccine technology for the production of protective immune responses.

摘要

开发更有效的HIV-1疫苗的新方法具有重要意义。在本报告中,我们分析了一种DNA疫苗接种方法在黑猩猩模型系统中的免疫原性和有效性。三只黑猩猩接种了表达env、rev、gag和pol蛋白的DNA构建体。这些动物对这些蛋白产生了特异性细胞反应,尽管不同动物的反应性质有所不同。我们证明,DNA疫苗接种导致CD8介导的对表达同源B亚型包膜的靶细胞以及表达异源E亚型包膜的靶细胞的杀伤。此外,血清阴性个体接种了表达env、rev蛋白的DNA构建体。这些研究为使用DNA疫苗技术产生保护性免疫反应提供了重要的基准。

相似文献

1
HIV-1 DNA based vaccine induces a CD8 mediated cross-clade CTL response.基于HIV-1 DNA的疫苗可诱导CD8介导的跨亚型细胞毒性T淋巴细胞反应。
Dev Biol Stand. 1998;95:147-53.
2
Efficient CD8+ T cell response to the HIV-env V3 loop epitope from multiple virus isolates by a DNA prime/vaccinia virus boost (rWR and rMVA strains) immunization regime and enhancement by the cytokine IFN-gamma.通过DNA初免/痘苗病毒加强(rWR和rMVA株)免疫方案对来自多种病毒分离株的HIV-env V3环表位产生高效的CD8 + T细胞应答,并通过细胞因子IFN-γ增强该应答。
Virus Res. 2004 Sep 15;105(1):11-22. doi: 10.1016/j.virusres.2004.04.008.
3
Multiprotein HIV type 1 clade B DNA/MVA vaccine: construction, safety, and immunogenicity in Macaques.多蛋白1型B亚型HIV DNA/MVA疫苗:猕猴中的构建、安全性及免疫原性
AIDS Res Hum Retroviruses. 2004 Jun;20(6):654-65. doi: 10.1089/0889222041217419.
4
Studies on the cross-clade and cross-species conservation of HIV-1 Gag-specific CD8 and CD4 T cell responses elicited by a clade B DNA/MVA vaccine in macaques.B亚型DNA/MVA疫苗在猕猴中引发的HIV-1 Gag特异性CD8和CD4 T细胞应答的跨分支和跨物种保守性研究。
Virology. 2005 Mar 30;334(1):124-33. doi: 10.1016/j.virol.2005.01.026.
5
Vaccination of seronegative volunteers with a human immunodeficiency virus type 1 env/rev DNA vaccine induces antigen-specific proliferation and lymphocyte production of beta-chemokines.用1型人类免疫缺陷病毒env/rev DNA疫苗对血清阴性志愿者进行接种可诱导抗原特异性增殖以及β趋化因子的淋巴细胞产生。
J Infect Dis. 2000 Feb;181(2):476-83. doi: 10.1086/315229.
6
Clustered epitopes within the Gag-Pol fusion protein DNA vaccine enhance immune responses and protection against challenge with recombinant vaccinia viruses expressing HIV-1 Gag and Pol antigens.Gag-Pol融合蛋白DNA疫苗中的聚集表位增强免疫反应,并提供针对表达HIV-1 Gag和Pol抗原的重组痘苗病毒攻击的保护作用。
Virology. 2005 Feb 20;332(2):467-79. doi: 10.1016/j.virol.2004.09.043.
7
Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.增强重组痘苗病毒天坛株(MVA)免疫反应:利用表达Env以及细胞因子白细胞介素-12(IL-12)和干扰素-γ(IFN-γ)的MVA和DNA载体增强对HIV-1的免疫反应。
Virus Res. 2006 Mar;116(1-2):11-20. doi: 10.1016/j.virusres.2005.08.008. Epub 2005 Oct 7.
8
Preclinical evaluation of cellular immune responses elicited by a polyvalent DNA prime/protein boost HIV-1 vaccine.一种多价DNA初免/蛋白加强HIV-1疫苗引发的细胞免疫反应的临床前评估。
Virology. 2006 Mar 1;346(1):151-68. doi: 10.1016/j.virol.2005.10.038. Epub 2005 Dec 2.
9
Immunogenicity of a recombinant human immunodeficiency virus (HIV)-canarypox vaccine in HIV-seronegative Ugandan volunteers: results of the HIV Network for Prevention Trials 007 Vaccine Study.重组人免疫缺陷病毒(HIV)-金丝雀痘疫苗在乌干达HIV血清阴性志愿者中的免疫原性:HIV预防试验网络007疫苗研究结果
J Infect Dis. 2003 Mar 15;187(6):887-95. doi: 10.1086/368020. Epub 2003 Mar 6.
10
Influence of polypeptide size and intracellular sorting on the induction of epitope-specific CTL responses by DNA vaccines in a mouse model.多肽大小和细胞内分选对小鼠模型中DNA疫苗诱导表位特异性CTL反应的影响。
Vaccine. 2004 Apr 16;22(13-14):1732-43. doi: 10.1016/j.vaccine.2004.01.035.

引用本文的文献

1
Recent Progress in the Discovery and Development of Monoclonal Antibodies against Viral Infections.抗病毒感染单克隆抗体发现与开发的最新进展
Biomedicines. 2022 Aug 2;10(8):1861. doi: 10.3390/biomedicines10081861.
2
Advances in gene-based vaccine platforms to address the COVID-19 pandemic.基于基因的疫苗平台在应对 COVID-19 大流行方面的进展。
Adv Drug Deliv Rev. 2021 Mar;170:113-141. doi: 10.1016/j.addr.2021.01.003. Epub 2021 Jan 7.
3
DNA immunization as a technology platform for monoclonal antibody induction.DNA免疫作为诱导单克隆抗体的技术平台。
Emerg Microbes Infect. 2016 Apr 6;5(4):e33. doi: 10.1038/emi.2016.27.
4
Harnessing DNA-induced immune responses for improving cancer vaccines.利用 DNA 诱导的免疫反应来改进癌症疫苗。
Hum Vaccin Immunother. 2012 Nov 1;8(11):1682-93. doi: 10.4161/hv.22345. Epub 2012 Oct 30.
5
Vaccination of mice with MUC1 cDNA suppresses the development of lung metastases.用MUC1 cDNA对小鼠进行疫苗接种可抑制肺转移的发生。
Clin Exp Metastasis. 2002;19(8):689-96. doi: 10.1023/a:1021332932531.
6
Simian immunodeficiency virus (SIV) gag DNA-vaccinated rhesus monkeys develop secondary cytotoxic T-lymphocyte responses and control viral replication after pathogenic SIV infection.用猿猴免疫缺陷病毒(SIV)gag DNA疫苗接种的恒河猴在感染致病性SIV后会产生继发性细胞毒性T淋巴细胞反应并控制病毒复制。
J Virol. 2000 Aug;74(16):7485-95. doi: 10.1128/jvi.74.16.7485-7495.2000.